Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
Why It's Important: Amgen reported a double beat Thursday after the market close and offered an update on its obesity drug pipeline. While pulling the plug on an early-stage oral obesity drug, codenamed "AMG 786," the company said it was "differentially investing" in MariTide and a number of preclinical assets.Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma company after it revealed significant progress with it weight-loss drug candidate.
凱西·伍德經營的 Ark Invest 週五收購了一家生物製藥公司的股票此前它透露其減肥候選藥物取得了重大進展。
What Happened: Ark, through its ARK Genomic Revolution ETF (CBOE: ARKG), bought 11,360 shares of Amgen, Inc. (NASDAQ:AMGN), which rallied nearly 12% on Friday. The purchase would have been worth $3.54 million.
發生了什麼：方舟通過其方舟基因革命ETF（芝加哥期權交易所：ARKG）購買了安進公司（納斯達克股票代碼：AMGN）的11,360股股票，週五上漲了近12％。此次收購將價值354萬美元。
Following Friday's purchase, Amgen's weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund.
繼週五的收購之後，安進在ARKG中的權重爲1.06％，這要歸因於該交易所交易基金持有的51,712股股票。
Why It's Important: Amgen reported a double beat Thursday after the market close and offered an update on its obesity drug pipeline. While pulling the plug on an early-stage oral obesity drug, codenamed "AMG 786," the company said it was "differentially investing" in MariTide and a number of preclinical assets.
爲何重要：安進週四在市場收盤後公佈了雙倍漲幅，並提供了其肥胖藥物管道的最新情況。在取消代號爲 “AMG 786” 的早期口服肥胖藥物時，該公司表示正在 “差異化投資” MariTide和一些臨床前資產。
MariTide, formerly AMG 133, is an injectable form of a drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1. It is currently being evaluated in a Phase 2 obesity trial.
MariTide，前身爲AMG 133，是一種靶向兩種腸道激素的可注射藥物——胃抑制性多肽受體（GIP）和胰高血糖素樣肽 1（即 GLP-1）。目前正在進行2期肥胖試驗的評估。
"We're seeing a differentiated profile of MariTide and are confident that it will address important unmet medical needs, obesity, obesity-related conditions, and diabetes," said Chief Scientific Officer Jay Bradner.
首席科學官傑伊·布拉德納說：“我們看到了MariTide的差異化概況，並有信心它將解決尚未滿足的重要醫療需求、肥胖、肥胖相關疾病和糖尿病。”
The top-line 52-week data from the 11-arm Phase 2 study is on track for a readout in late 2024, the company said.
該公司表示，來自11個分組的2期研究的52周主要數據有望在2024年底公佈。
The weight-loss drug market is estimated at a staggering $100 billion, with Novo Nordisk and Eli Lilly currently dominating the segment.
減肥藥市場估計達到驚人的1000億美元，諾和諾德和禮來目前在該細分市場中佔據主導地位。
ARKG closed Friday's session up 3.51% at $25.04, according to Benzinga Pro data.
根據Benzinga Pro的數據，ARKG週五收盤上漲3.51％，至25.04美元。
Photo: Shutterstock
照片：Shutterstock
